Palantir's 'Glowing' NHS Claims Are Meaningless Without Independent Audit
AI-generated image · US National Wire
Opinion: Until the NHS provides audited clinical outcomes, Palantir's self-reported wins remain vaporware.
In the world of health tech, there is a vast chasm between a software vendor claiming a 'win' and a clinical outcome that actually saves lives. Right now, Palantir is leaping across that chasm with a level of confidence that should make any evidence-based practitioner shudder.
As first reported by The Register, Palantir UK senior vice president and former deputy leader of the Labour Party Tom Watson has been actively claiming that the company's Federated Data Platform (FDP) is making a tangible difference in the UK's National Health Service (NHS). Watson has pointed to figures from institutions like Chelsea and Westminster Hospital, University Hospitals of Derby and Burton, and Northampton General Hospital as evidence of benefit. But when pressed in a prepared video, Watson admitted the company cannot prove that every procedure performed happened because of their software.
This is the core of the problem. Palantir is asking the public and the government to accept anecdotal success as systemic proof.
According to The Register, NHS England previously claimed that 137 out of 139 trusts using the platform reported benefits, including a claim that an Inpatient Care Coordination Solution tool helped hospitals perform procedures on an additional 111,589 patients. However, these numbers are already crumbling under scrutiny. A Freedom of Information request revealed that nearly a third of the trusts using the platform were actually performing fewer patient procedures than they were before the system went live.
Furthermore, the Office for Statistics Regulation (OSR) has stepped in to examine the evidence used to justify the £330 million contract awarded to the Palantir-led consortium in November 2023. The OSR noted that NHS England had to admit it needed to communicate performance claims more clearly, specifically adding a caveat that it could not draw conclusions about cause and effect because other variables—such as industrial action or staffing changes—had not been controlled for.
Even the leadership at NHS England seems to recognize the gap between Palantir's marketing and reality. Sir Jim Mackey, CEO of NHS England, told the Health and Social Care Committee that he intends to tell Palantir to clear any future benefit claims with his team. Most damningly, Mackey admitted that enforcing this requirement could be difficult contractually.
It is a precarious position for the NHS to be in: paying millions for a platform while the vendor is essentially grading its own homework. While Watson has dismissed concerns as 'misinformation,' the fact remains that the evidence is currently self-reported and uncontrolled.
There is a glimmer of hope. The Register reports that in February 2026, NHS England contracted Imperial College Projects to conduct an independent evaluation of the FDP. This is the only metric that matters. Until that independent, audited evidence is produced, Palantir's claims of 'making a difference' are nothing more than corporate storytelling. In healthcare, 'probably' isn't good enough, and 'trust us' is not a clinical strategy.